Pediatric Radiology

, Volume 42, Issue 1, pp 76–81 | Cite as

Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers

  • H. Theodore Harcke
  • Kimberly L. Stevenson
  • Heidi H. Kecskemethy
  • Steven J. Bachrach
  • Leslie E. Grissom
Original Article



In the nonambulatory cerebral palsy (CP) population with a prior history of fracture, the use of pamidronate is not always effective in preventing further fractures.


To test the hypothesis that when fractures occur after cyclic pamidronate, they will be at the proximal or distal end of a pamidronate band.

Materials and methods

Retrospective review of our CP patient database revealed 53 children who had received one or more complete courses of pamidronate therapy (five cycles over 12 months). Medical records were screened to identify children who had sustained a fracture or fractures after completing treatment.


Of 53 patients treated with pamidronate, only 14 sustained fractures after treatment. Radiographs were available for 11 patients, showing 19 fractures. Sixty-three percent of these fractures were located at a junction with pamidronate bands but not within the bands.


We propose stress risers as the mechanism for fractures that have occurred where bone mineral density abruptly changes as a result of cyclic administration of pamidronate. We show a theoretical example of how alternative dosing might reduce the ratio and therefore decrease the chance of formation of a stress riser.


Bisphosphonates Cerebral palsy Fractures Stress risers Children 


  1. 1.
    Bachrach SJ, Kecskemethy HH, Harcke HT et al (2010) Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. Dev Med Child Neurol 52:837–842PubMedCrossRefGoogle Scholar
  2. 2.
    Plotkin H, Bruzoni M, Coughlin S et al (2006) Low doses of pamidronate for the treatment of osteopenia in children with cerebral palsy. Dev Med Child Neurol 48:709–712PubMedCrossRefGoogle Scholar
  3. 3.
    Bachrach SJ, Kecskemethy HH, Harcke HT et al (2006) Pamidronate treatment and post treatment bone density in children with spastic quadriplegic cerebral palsy. J Clin Densitom 9:167–174PubMedCrossRefGoogle Scholar
  4. 4.
    Henderson RC, Lark RK, Kecskemethy HH et al (2002) Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 141:644–651PubMedCrossRefGoogle Scholar
  5. 5.
    Shaw NJ, White CP, Fraser WD et al (1994) Osteopenia in cerebral palsy. Arch Dis Child 71:235–238PubMedCrossRefGoogle Scholar
  6. 6.
    Rauch F, Munns C, Land C et al (2006) Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 91:1268–1274PubMedCrossRefGoogle Scholar
  7. 7.
    Marx RE, Sawatari Y, Fortin M et al (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575PubMedCrossRefGoogle Scholar
  8. 8.
    Whyte MP, Wenkert D, Clements KL et al (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457–463PubMedCrossRefGoogle Scholar
  9. 9.
    Grissom LE, Harcke HT (2003) Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 33:226–229PubMedGoogle Scholar
  10. 10.
    Staheli L (2006) Practice of pediatric orthopedics, 2nd ed. Lipincott, Williams, and Wilkins, Philadelphia p 267Google Scholar
  11. 11.
    Alford JW, Bradley MP, Fadale PD et al (2007) Resorbable fillers reduce stress risers from empty screw holes. J Trauma 63:647–654PubMedCrossRefGoogle Scholar
  12. 12.
    Miller F, Dabney KW, Rang M et al (1995) Complications in cerebral palsy treatment. In: Epps CH Jr, Bowen JR (eds) Complications in pediatric orthopaedic surgery. Lippincott, PhiladelphiaGoogle Scholar
  13. 13.
    Hernandez CJ (2008) How can bone turnover modify bone strength independent of bone mass? Bone 42:1014–1020PubMedCrossRefGoogle Scholar
  14. 14.
    Andiran N, Alikasifoglu A, Gone N et al (2008) Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation. J Pediatr Endocrinol Metab 21:63–72PubMedCrossRefGoogle Scholar
  15. 15.
    Henderson RC, Lark RK, Newman JE et al (2002) Pediatric reference data for dual x-ray absorptiometric measures of bone density in the distal femur. AJR 178:439–443PubMedGoogle Scholar
  16. 16.
    Zemel BS, Stallings VA, Leonard MB et al (2009) Revised pediatric reference data for the lateral distal femur measured by dual energy x-ray absorptiometry. J Clin Densitom 12:207–218PubMedCrossRefGoogle Scholar
  17. 17.
    Aspenberg P (2009) Bisphosphonates and fatigue fractures. IBMS BoneKEy 6:465–467CrossRefGoogle Scholar
  18. 18.
    Neviaser AS, Lane JM, Lenart BA et al (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346–350PubMedCrossRefGoogle Scholar
  19. 19.
    Ing-Lorenzini K, Desmeules J, Plachta O et al (2009) Low-energy femoral fractures associated with the long-term use of bisphosphonates. Drug Saf 32:775–785PubMedCrossRefGoogle Scholar
  20. 20.
    Bishop NE, Ferguson S, Tepic S (1996) Porosity reduction in bone cement at the cement-stem interface. J Bone Joint Surg 78B:349–356Google Scholar
  21. 21.
    Rauch F, Cornibert S, Cheung M et al (2007) Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40:821–827PubMedCrossRefGoogle Scholar
  22. 22.
    Harcke HT, Taylor A, Bachrach S et al (1998) Lateral femoral scan: an alternative method for assessing bone mineral density in children with cerebral palsy. Pediatr Radiol 28:241–246PubMedCrossRefGoogle Scholar
  23. 23.
    Ward KA, Adams JE, Freemont TJ et al (2007) Can bisphosphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos Int 18:1137–1140PubMedCrossRefGoogle Scholar
  24. 24.
    Gandrud LM, Cheung JC, Daniels MW et al (2003) Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metabol 16:887–892CrossRefGoogle Scholar
  25. 25.
    Steelman J, Zeitler P (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 142:417–423PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • H. Theodore Harcke
    • 1
  • Kimberly L. Stevenson
    • 1
  • Heidi H. Kecskemethy
    • 1
  • Steven J. Bachrach
    • 1
  • Leslie E. Grissom
    • 1
  1. 1.Alfred I. duPont Hospital for ChildrenWilmingtonUSA

Personalised recommendations